Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

J&J Awards First Grants from AI Surgery Fund, Advancing Innovation in Surgical Technology

J&J Awards First Grants from AI Surgery Fund, Advancing Innovation in Surgical Technology

Johnson & Johnson (J&J) has taken a significant step forward in promoting artificial intelligence (AI) applications in surgery by awarding the first grants from its recently established Polyphonic AI Fund. This initiative, launched earlier this year in collaboration with NVIDIA and Amazon, aims to support and accelerate the development of AI-driven solutions in surgical care.

NoahAI News10/27/2025
Organon CEO Resigns Amid Improper Sales Tactics Investigation

Organon CEO Resigns Amid Improper Sales Tactics Investigation

Organon, the women's health-focused pharmaceutical company spun off from Merck in 2021, is facing a significant leadership shake-up following an internal investigation into questionable sales practices. The probe has led to the resignation of CEO Kevin Ali and the termination of the company's head of U.S. commercial and government affairs.

NoahAI News10/27/2025
Corcym and CardioPrecision Unveil Robotic Heart Valve Surgery Innovation

Corcym and CardioPrecision Unveil Robotic Heart Valve Surgery Innovation

In a significant advancement for cardiac surgery, Corcym and CardioPrecision have joined forces to develop a novel robotic approach to aortic valve replacement. This collaboration aims to combine the benefits of minimally invasive procedures with the long-term advantages of traditional open-heart surgery.

NoahAI News10/27/2025
Zenas Biopharma's Obexelimab Shows Promise in Phase 2 Multiple Sclerosis Study

Zenas Biopharma's Obexelimab Shows Promise in Phase 2 Multiple Sclerosis Study

Zenas Biopharma has reported significant positive results from its phase 2 MoonStone study of obexelimab, a bifunctional monoclonal antibody, in patients with relapsing multiple sclerosis (MS). The trial demonstrated a 95% reduction in new brain lesions, marking a potentially important development in MS treatment.

NoahAI News10/27/2025
Machinify Expands AI-Powered Payment Integrity Platform with $670M Acquisition of Performant Healthcare

Machinify Expands AI-Powered Payment Integrity Platform with $670M Acquisition of Performant Healthcare

Machinify, a leading healthcare data company, has closed its acquisition of Performant Healthcare for approximately $670 million, marking a significant expansion of its AI-powered platform in the healthcare payment integrity sector. The deal, which combines Machinify's advanced artificial intelligence capabilities with Performant's expertise in audit and recovery, aims to deliver enhanced services to a broader range of organizations, including government programs.

NoahAI News10/27/2025
BridgeBio's Limb-Girdle Drug Shows Promise in Late-Stage Study, Paving Way for FDA Discussions

BridgeBio's Limb-Girdle Drug Shows Promise in Late-Stage Study, Paving Way for FDA Discussions

BridgeBio Pharma has announced positive results from a late-stage study of its experimental drug BBP-418 for limb-girdle muscular dystrophy type 2I/R9, positioning the company to engage with U.S. regulators about a potential approval filing. The study's success marks a significant milestone in the treatment of this rare genetic condition and could lead to the first approved therapy for affected patients.

NoahAI News10/27/2025
Hemab Therapeutics Secures $157M Series C Funding to Advance Rare Blood Disorder Treatments

Hemab Therapeutics Secures $157M Series C Funding to Advance Rare Blood Disorder Treatments

Hemab Therapeutics, a biotech company focused on developing treatments for rare and underserved bleeding disorders, has successfully raised $157 million in a Series C funding round. The financing, led by Sofinnova Partners, will support the advancement of Hemab's pipeline and clinical candidates for conditions such as Glanzmann thrombasthenia and von Willebrand disease.

NoahAI News10/27/2025
MapLight Therapeutics Goes Public with $250M IPO to Challenge Schizophrenia Market

MapLight Therapeutics Goes Public with $250M IPO to Challenge Schizophrenia Market

MapLight Therapeutics has successfully launched its initial public offering (IPO) on the Nasdaq, raising $250 million to fund the development of its challenger to Bristol Myers Squibb's schizophrenia medication, Cobenfy. The California-based biotech company's stock is now trading under the ticker "MPLT," marking a significant milestone in the pharmaceutical industry's ongoing efforts to advance treatments for central nervous system disorders.

NoahAI News10/27/2025
BridgeBio's Phase 3 Success Paves Way for FDA Filing in Rare Muscular Dystrophy

BridgeBio's Phase 3 Success Paves Way for FDA Filing in Rare Muscular Dystrophy

BridgeBio Pharma has announced groundbreaking results from its phase 3 trial for BBP-418, a novel treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The study's success has positioned the company to file for FDA approval, potentially bringing a new therapy to patients with this rare genetic disorder.

NoahAI News10/27/2025
GSK Expands ADC Portfolio with $357M Syndivia Deal for Prostate Cancer Candidate

GSK Expands ADC Portfolio with $357M Syndivia Deal for Prostate Cancer Candidate

GlaxoSmithKline (GSK) has inked a $357 million agreement with French biotech Syndivia to develop a preclinical antibody-drug conjugate (ADC) for prostate cancer, further solidifying its position in the rapidly growing ADC market. The deal comes on the heels of the European Society for Medical Oncology (ESMO) congress in Berlin, where ADCs took center stage.

NoahAI News10/27/2025
Coya Therapeutics' Daniel Barvin: A Personal Mission to End Genetic ALS and FTD

Coya Therapeutics' Daniel Barvin: A Personal Mission to End Genetic ALS and FTD

Daniel Barvin, VP of Operations and Patient Advocacy at Coya Therapeutics, is spearheading a deeply personal fight against amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). As a carrier of the C9orf72 mutation, which significantly increases his risk of developing these neurodegenerative diseases, Barvin has transitioned from a successful career in wealth management to become a key player in the biotech industry's battle against ALS and FTD.

NoahAI News10/27/2025
Breakthrough in Huntington's Disease Treatment: Gene Therapy Shows Promise Amid Ongoing Research

Breakthrough in Huntington's Disease Treatment: Gene Therapy Shows Promise Amid Ongoing Research

In a groundbreaking development for Huntington's disease (HD) treatment, uniQure's gene therapy has demonstrated significant success in slowing disease progression. This milestone has reinvigorated the field, with several other promising therapies now in advanced stages of development. As the pharmaceutical industry races to bring the first disease-modifying treatment to market, we examine the latest advancements and their potential impact on patients.

NoahAI News10/27/2025
«1...678...67»